Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy

Koji Kato, Ryo Maemura, Manabu Wakamatsu, Ayako Yamamori, Motoharu Hamada, Shinsuke Kataoka, Atsushi Narita, Shunsuke Miwata, Yuko Sekiya, Nozomu Kawashima, Kyogo Suzuki, Kotaro Narita, Sayoko Doisaki, Hideki Muramatsu, Hirotoshi Sakaguchi, Kimikazu Matsumoto, Yuka Koike, Osamu Onodera, Makiko Kaga, Nobuyuki ShimozawaNao Yoshida

研究成果: ジャーナルへの寄稿記事

抄録

Objective: The prognosis of adrenoleukodystrophy (ALD)with neurological involvement is generally dismal; however, allogeneic stem cell transplantation (SCT) is recognized as effective to stabilize or improve the clinical symptoms of ALD. Herein, we report the clinical outcomes of patients with ALD who consecutively underwent allogeneic stem cell transplantation with reduced intensity conditioning at our institution. Patients: Sixteen patients with ALD, who were symptomatic (n = 14) or presymptomatic (n = 2), received SCT from 2010 to 2016. The stem cell source was cord blood (n = 14), or bone marrow from a human leukocyte antigen identical sibling (n = 2). The conditioning regimen prior to transplantation was reduced intensity and consisted of fludarabine (125 mg/m2), melphalan (140 mg/m2) and low dose total body irradiation (TBI) of 4Gy (n = 15) or 3Gy (n = 1). Results: Primary engraftment was obtained in 11 patients, and 4 of the 5 patients who lost the primary graft received a second cord blood transplantation and were engrafted. Five years overall and event-free survival were 90.9% and 61.1% respectively, with a median of 45 months (range 16–91). Loes score stabilized or improved by 18 months after transplantation except for patients with internal capsule involvement. Conclusion: Allogeneic SCT with reduced intensity conditioning for patients with ALD was safely performed without major transplant-related complications even in symptomatic patients and neurological symptoms were stabilized after SCT in patients without internal capsule involvement.

元の言語英語
ページ(範囲)1-6
ページ数6
ジャーナルMolecular Genetics and Metabolism Reports
18
DOI
出版物ステータス出版済み - 3 1 2019

Fingerprint

Adrenoleukodystrophy
Stem Cell Transplantation
Internal Capsule
Transplantation
Fetal Blood
Transplants
Conditioning (Psychology)
Melphalan
Whole-Body Irradiation
HLA Antigens
Disease-Free Survival
Siblings
Stem Cells
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Endocrinology

これを引用

Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. / Kato, Koji; Maemura, Ryo; Wakamatsu, Manabu; Yamamori, Ayako; Hamada, Motoharu; Kataoka, Shinsuke; Narita, Atsushi; Miwata, Shunsuke; Sekiya, Yuko; Kawashima, Nozomu; Suzuki, Kyogo; Narita, Kotaro; Doisaki, Sayoko; Muramatsu, Hideki; Sakaguchi, Hirotoshi; Matsumoto, Kimikazu; Koike, Yuka; Onodera, Osamu; Kaga, Makiko; Shimozawa, Nobuyuki; Yoshida, Nao.

:: Molecular Genetics and Metabolism Reports, 巻 18, 01.03.2019, p. 1-6.

研究成果: ジャーナルへの寄稿記事

Kato, K, Maemura, R, Wakamatsu, M, Yamamori, A, Hamada, M, Kataoka, S, Narita, A, Miwata, S, Sekiya, Y, Kawashima, N, Suzuki, K, Narita, K, Doisaki, S, Muramatsu, H, Sakaguchi, H, Matsumoto, K, Koike, Y, Onodera, O, Kaga, M, Shimozawa, N & Yoshida, N 2019, 'Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy', Molecular Genetics and Metabolism Reports, 巻. 18, pp. 1-6. https://doi.org/10.1016/j.ymgmr.2018.11.001
Kato, Koji ; Maemura, Ryo ; Wakamatsu, Manabu ; Yamamori, Ayako ; Hamada, Motoharu ; Kataoka, Shinsuke ; Narita, Atsushi ; Miwata, Shunsuke ; Sekiya, Yuko ; Kawashima, Nozomu ; Suzuki, Kyogo ; Narita, Kotaro ; Doisaki, Sayoko ; Muramatsu, Hideki ; Sakaguchi, Hirotoshi ; Matsumoto, Kimikazu ; Koike, Yuka ; Onodera, Osamu ; Kaga, Makiko ; Shimozawa, Nobuyuki ; Yoshida, Nao. / Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. :: Molecular Genetics and Metabolism Reports. 2019 ; 巻 18. pp. 1-6.
@article{f0889433acbb42a3ac8f7216eeb5d496,
title = "Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy",
abstract = "Objective: The prognosis of adrenoleukodystrophy (ALD)with neurological involvement is generally dismal; however, allogeneic stem cell transplantation (SCT) is recognized as effective to stabilize or improve the clinical symptoms of ALD. Herein, we report the clinical outcomes of patients with ALD who consecutively underwent allogeneic stem cell transplantation with reduced intensity conditioning at our institution. Patients: Sixteen patients with ALD, who were symptomatic (n = 14) or presymptomatic (n = 2), received SCT from 2010 to 2016. The stem cell source was cord blood (n = 14), or bone marrow from a human leukocyte antigen identical sibling (n = 2). The conditioning regimen prior to transplantation was reduced intensity and consisted of fludarabine (125 mg/m2), melphalan (140 mg/m2) and low dose total body irradiation (TBI) of 4Gy (n = 15) or 3Gy (n = 1). Results: Primary engraftment was obtained in 11 patients, and 4 of the 5 patients who lost the primary graft received a second cord blood transplantation and were engrafted. Five years overall and event-free survival were 90.9{\%} and 61.1{\%} respectively, with a median of 45 months (range 16–91). Loes score stabilized or improved by 18 months after transplantation except for patients with internal capsule involvement. Conclusion: Allogeneic SCT with reduced intensity conditioning for patients with ALD was safely performed without major transplant-related complications even in symptomatic patients and neurological symptoms were stabilized after SCT in patients without internal capsule involvement.",
author = "Koji Kato and Ryo Maemura and Manabu Wakamatsu and Ayako Yamamori and Motoharu Hamada and Shinsuke Kataoka and Atsushi Narita and Shunsuke Miwata and Yuko Sekiya and Nozomu Kawashima and Kyogo Suzuki and Kotaro Narita and Sayoko Doisaki and Hideki Muramatsu and Hirotoshi Sakaguchi and Kimikazu Matsumoto and Yuka Koike and Osamu Onodera and Makiko Kaga and Nobuyuki Shimozawa and Nao Yoshida",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ymgmr.2018.11.001",
language = "English",
volume = "18",
pages = "1--6",
journal = "Molecular Genetics and Metabolism Reports",
issn = "2214-4269",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy

AU - Kato, Koji

AU - Maemura, Ryo

AU - Wakamatsu, Manabu

AU - Yamamori, Ayako

AU - Hamada, Motoharu

AU - Kataoka, Shinsuke

AU - Narita, Atsushi

AU - Miwata, Shunsuke

AU - Sekiya, Yuko

AU - Kawashima, Nozomu

AU - Suzuki, Kyogo

AU - Narita, Kotaro

AU - Doisaki, Sayoko

AU - Muramatsu, Hideki

AU - Sakaguchi, Hirotoshi

AU - Matsumoto, Kimikazu

AU - Koike, Yuka

AU - Onodera, Osamu

AU - Kaga, Makiko

AU - Shimozawa, Nobuyuki

AU - Yoshida, Nao

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objective: The prognosis of adrenoleukodystrophy (ALD)with neurological involvement is generally dismal; however, allogeneic stem cell transplantation (SCT) is recognized as effective to stabilize or improve the clinical symptoms of ALD. Herein, we report the clinical outcomes of patients with ALD who consecutively underwent allogeneic stem cell transplantation with reduced intensity conditioning at our institution. Patients: Sixteen patients with ALD, who were symptomatic (n = 14) or presymptomatic (n = 2), received SCT from 2010 to 2016. The stem cell source was cord blood (n = 14), or bone marrow from a human leukocyte antigen identical sibling (n = 2). The conditioning regimen prior to transplantation was reduced intensity and consisted of fludarabine (125 mg/m2), melphalan (140 mg/m2) and low dose total body irradiation (TBI) of 4Gy (n = 15) or 3Gy (n = 1). Results: Primary engraftment was obtained in 11 patients, and 4 of the 5 patients who lost the primary graft received a second cord blood transplantation and were engrafted. Five years overall and event-free survival were 90.9% and 61.1% respectively, with a median of 45 months (range 16–91). Loes score stabilized or improved by 18 months after transplantation except for patients with internal capsule involvement. Conclusion: Allogeneic SCT with reduced intensity conditioning for patients with ALD was safely performed without major transplant-related complications even in symptomatic patients and neurological symptoms were stabilized after SCT in patients without internal capsule involvement.

AB - Objective: The prognosis of adrenoleukodystrophy (ALD)with neurological involvement is generally dismal; however, allogeneic stem cell transplantation (SCT) is recognized as effective to stabilize or improve the clinical symptoms of ALD. Herein, we report the clinical outcomes of patients with ALD who consecutively underwent allogeneic stem cell transplantation with reduced intensity conditioning at our institution. Patients: Sixteen patients with ALD, who were symptomatic (n = 14) or presymptomatic (n = 2), received SCT from 2010 to 2016. The stem cell source was cord blood (n = 14), or bone marrow from a human leukocyte antigen identical sibling (n = 2). The conditioning regimen prior to transplantation was reduced intensity and consisted of fludarabine (125 mg/m2), melphalan (140 mg/m2) and low dose total body irradiation (TBI) of 4Gy (n = 15) or 3Gy (n = 1). Results: Primary engraftment was obtained in 11 patients, and 4 of the 5 patients who lost the primary graft received a second cord blood transplantation and were engrafted. Five years overall and event-free survival were 90.9% and 61.1% respectively, with a median of 45 months (range 16–91). Loes score stabilized or improved by 18 months after transplantation except for patients with internal capsule involvement. Conclusion: Allogeneic SCT with reduced intensity conditioning for patients with ALD was safely performed without major transplant-related complications even in symptomatic patients and neurological symptoms were stabilized after SCT in patients without internal capsule involvement.

UR - http://www.scopus.com/inward/record.url?scp=85056756721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056756721&partnerID=8YFLogxK

U2 - 10.1016/j.ymgmr.2018.11.001

DO - 10.1016/j.ymgmr.2018.11.001

M3 - Article

AN - SCOPUS:85056756721

VL - 18

SP - 1

EP - 6

JO - Molecular Genetics and Metabolism Reports

JF - Molecular Genetics and Metabolism Reports

SN - 2214-4269

ER -